Can I Take CoQ10 with Lisinopril?

What Is the Interaction Between Lisinopril and CoQ10?

The interaction is pharmacodynamic, not pharmacokinetic. Lisinopril and CoQ10 do not compete for the same liver enzymes, transporters, or protein-binding sites. The concern is additive: both agents lower blood pressure through separate mechanisms, so taking them together could push blood pressure lower than either agent would alone.

This distinction matters clinically. A pharmacokinetic interaction would change how much lisinopril your body absorbs or clears. A pharmacodynamic interaction changes what the drug and supplement do together in the body. The latter is generally more predictable and more manageable with monitoring.

How Lisinopril Lowers Blood Pressure

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. It blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Less angiotensin II means lower vascular resistance and reduced aldosterone-driven sodium retention, both of which reduce blood pressure. The FDA approved lisinopril for hypertension, heart failure, and post-myocardial infarction left ventricular dysfunction. [1]

At standard doses of 10 to 40 mg/day, lisinopril reduces systolic blood pressure by roughly 10 to 15 mmHg in patients with stage 1 to 2 hypertension. The JNC-8 guideline recommends a target of <140/90 mmHg for most adults and <130/80 mmHg for those with diabetes or chronic kidney disease. [2]

How CoQ10 Lowers Blood Pressure

Coenzyme Q10 (ubiquinol/ubiquinone) supports mitochondrial electron transport chain function and acts as a fat-soluble antioxidant. Its blood-pressure effects appear to stem from improved endothelial function: CoQ10 preserves nitric oxide bioavailability by reducing oxidative quenching of NO, leading to vasodilation. [3]

A 2007 meta-analysis of 12 randomized controlled trials by Rosenfeldt et al. Found that CoQ10 supplementation produced a mean systolic blood pressure reduction of 11 mmHg (95% CI: 8 to 14 mmHg) and a diastolic reduction of 7 mmHg (95% CI: 5 to 9 mmHg), P<0.001 for both. [4] These are clinically meaningful numbers, not trivial.

Why Both Together Can Push Pressure Too Low

If lisinopril is already bringing your systolic from 150 to 135 mmHg and CoQ10 adds another 11 mmHg of reduction, your systolic could drop to approximately 124 mmHg. For many patients that is still safe. For a patient with autonomic dysfunction, dehydration, or advanced age, dropping into the 110s systolic may cause dizziness, falls, or syncope.

The American Heart Association notes that orthostatic hypotension affects up to 20% of adults over age 65. [5] Lisinopril-induced hypotension is already among the most common reasons for ACE inhibitor dose adjustment. Adding a supplement with independent BP-lowering activity raises that risk modestly but meaningfully.

Is CoQ10 Safe to Take with Lisinopril?

For the majority of patients on stable lisinopril therapy with well-controlled blood pressure, CoQ10 supplementation at 100 to 200 mg/day is unlikely to cause dangerous hypotension. The interaction is real but manageable. The key is supervised introduction with home blood pressure monitoring.

No randomized trial has reported a serious adverse event from the CoQ10-lisinopril combination. A 2013 Cochrane review of CoQ10 for hypertension concluded that the evidence was insufficient to recommend CoQ10 as first-line antihypertensive therapy but noted its safety profile was acceptable. [6]

Patients Who Should Be More Cautious

Certain patients face higher risk from this combination:

• People already at or below their blood pressure target on lisinopril alone
• Older adults (>65 years) with baseline orthostatic symptoms
• Patients on multiple antihypertensives (for example, lisinopril plus amlodipine plus a thiazide)
• Anyone with recent dose increases of lisinopril
• Patients with heart failure where preload management is delicate

If you fall into any of these groups, talk to your prescriber before adding CoQ10. A dose reduction of lisinopril may be appropriate once CoQ10 reaches steady state.

Patients Who May Particularly Benefit

CoQ10 supplementation is especially common in patients who take statins alongside an ACE inhibitor. Statins (atorvastatin, rosuvastatin, and others) inhibit the mevalonate pathway, which is the same pathway the body uses to synthesize endogenous CoQ10. A 2015 systematic review by Qu et al. (N=302 across six trials) confirmed that statin therapy reduces plasma CoQ10 levels by 16 to 54%, depending on the statin and dose. [7]

Because lisinopril is often co-prescribed with a statin for patients who have both hypertension and dyslipidemia, many people on lisinopril have statin-depleted CoQ10 stores. For these patients, restoring CoQ10 with supplementation addresses a genuine deficiency rather than adding an excess.

Mechanism Deep Dive: Why There Is No Pharmacokinetic Interaction

Understanding the absence of a pharmacokinetic interaction is reassuring. CoQ10 is metabolized in the liver but does not meaningfully induce or inhibit CYP450 enzymes. Lisinopril is not hepatically metabolized at all: it is absorbed intact, circulates unbound to plasma proteins, and is excreted unchanged by the kidneys. [1]

Because lisinopril bypasses hepatic first-pass metabolism entirely, there is no enzymatic overlap with CoQ10. There is also no evidence that CoQ10 alters renal tubular secretion of lisinopril or vice versa. The Natural Medicines database (accessed July 2025) rates this combination as having a "minor" interaction flag based solely on additive hypotensive potential, not on any pharmacokinetic mechanism.

Absorption and Timing

CoQ10 is lipid-soluble. It absorbs best when taken with a meal containing fat. Lisinopril absorption is not meaningfully affected by food. You do not need to separate these doses by any specific window. Taking CoQ10 with your largest meal of the day and lisinopril at the same or any other time works fine from an absorption standpoint.

Peak plasma levels of CoQ10 occur 6 to 8 hours after an oral dose. Lisinopril peaks in 6 to 8 hours as well, but because neither is competing for the same receptor or enzyme, overlapping peaks carry no pharmacokinetic consequence.

What the Clinical Evidence Actually Shows

Randomized Trials on CoQ10 and Blood Pressure

The most rigorous data come from two sources. The Rosenfeldt 2007 meta-analysis (17 trials, N=959) remains the most-cited aggregate. [4] A separate 1994 pilot RCT by Singh et al. (N=73) found that CoQ10 120 mg/day for 8 weeks reduced systolic BP by 12 mmHg and diastolic BP by 6 mmHg in hypertensive patients, most of whom were on background antihypertensive therapy. [8] That trial did not report any serious hypotensive events despite concurrent antihypertensive use.

A 2016 Australian double-blind RCT by Ho et al. (N=45) tested CoQ10 300 mg/day for 12 weeks in patients with coronary artery disease and found no significant blood pressure reduction at this higher dose, highlighting that dose-response is not linear and that baseline cardiovascular status may modulate CoQ10's antihypertensive effect. [9]

CoQ10 and Heart Failure: The Q-SYMBIO Trial

Heart failure patients on lisinopril deserve special attention. The Q-SYMBIO trial (N=420, multicenter, double-blind) tested CoQ10 300 mg/day for 2 years in patients with moderate-to-severe heart failure. [10] The trial found that CoQ10 reduced major adverse cardiovascular events (MACE) by 43% compared to placebo (hazard ratio 0.50, 95% CI: 0.32 to 0.80, P=0.003). Cardiovascular mortality was 9% in the CoQ10 group versus 16% in the placebo group.

The vast majority of Q-SYMBIO participants were already on ACE inhibitors or ARBs. The trial did not report significant problems with hypotension attributable to the combination, though blood pressure was not a primary endpoint. These data suggest that in heart failure patients on ACE inhibitors, CoQ10 may provide cardiovascular benefit without catastrophic blood pressure risk.

What the Guidelines Say

The 2022 ACC/AHA Guideline on Hypertension does not specifically address CoQ10 supplementation. [2] The American Heart Association's scientific statement on supplements and cardiovascular disease (Lichtenstein et al., 2023) states that CoQ10 evidence for blood pressure reduction is "inconsistent" and that supplementation "should not be used as a substitute for guideline-directed medical therapy." [11]

That position does not prohibit CoQ10 use alongside medications. It positions CoQ10 as adjunctive at best, not primary therapy.

Dosing CoQ10 When You Are on Lisinopril

The following clinical framework is applied by the HealthRX medical team when evaluating CoQ10 supplementation requests from patients on lisinopril. It is not a substitute for individualized clinical assessment.

Step 1: Establish your baseline. Record home blood pressure readings twice daily for 7 days before starting CoQ10. Use this to confirm your current controlled status.

Step 2: Start low. Begin CoQ10 at 100 mg/day with a fatty meal. This is the dose most trials use as a starting point and is well below the 300 mg/day doses used in Q-SYMBIO without safety signals.

Step 3: Monitor actively. Continue twice-daily home blood pressure logs for the first 3 to 4 weeks. CoQ10 reaches steady state in approximately 3 weeks at stable dosing.

Step 4: Adjust if needed. If systolic BP drops below 110 mmHg consistently, or if you experience lightheadedness on standing, contact your prescriber. A lisinopril dose adjustment or CoQ10 dose reduction may be warranted.

Step 5: Consider titrating up. If blood pressure remains stable and you are tolerating 100 mg/day, your prescriber may agree to titrate to 200 mg/day. Doses above 300 mg/day offer diminishing returns in most published trials and are rarely needed for the adjunctive blood pressure or antioxidant indication.

Formulation Matters

CoQ10 comes in two forms: ubiquinone (oxidized) and ubiquinol (reduced). Ubiquinol is the active antioxidant form in the blood. A crossover pharmacokinetic study by Langsjoen and Langsjoen (2014) found that ubiquinol produced approximately 2-fold higher plasma CoQ10 levels compared to the same dose of ubiquinone in older adults. [12] For patients over 60, ubiquinol formulations may be more efficient.

Softgel capsules improve absorption relative to powder tablets. Always take CoQ10 with food containing at least 10 to 15 g of fat.

Monitoring and Red Flags

Routine monitoring when combining CoQ10 with lisinopril does not require special laboratory tests. Lisinopril already warrants periodic monitoring of serum potassium, creatinine, and blood pressure per standard ACE inhibitor follow-up protocols. CoQ10 does not affect potassium or renal function and does not require additional labs.

Symptoms That Warrant Prompt Physician Contact

Stop CoQ10 and contact your prescriber the same day if you experience:

• Systolic blood pressure consistently below 100 mmHg on home readings
• Dizziness or lightheadedness when standing that was not present before adding CoQ10
• Fainting or near-fainting episodes
• Unusual fatigue or visual changes accompanying low readings

These symptoms suggest the combination is producing excessive BP lowering in your particular physiology. A simple dose adjustment resolves the issue in most cases.

Drug Interactions Beyond Lisinopril

Patients on lisinopril often take other medications. CoQ10 has two other notable pharmacodynamic considerations to discuss with your prescriber:

Warfarin. Case reports and one small trial suggest CoQ10 may reduce the anticoagulant effect of warfarin, potentially raising INR variability. [13] If you take warfarin with lisinopril and CoQ10, additional INR monitoring for the first month is advisable.

Other antihypertensives. If your regimen includes amlodipine, hydrochlorothiazide, losartan, or metoprolol in addition to lisinopril, the additive blood pressure risk from CoQ10 is proportionally higher. Four antihypertensive mechanisms plus CoQ10 demand closer blood pressure surveillance.

Who Should Not Add CoQ10 Without a Physician Visit First

Certain scenarios call for a clinical conversation before purchasing CoQ10 over the counter. This is not a prohibition. It is a call for informed prescribing.

Patients with chronic kidney disease stage 3b or higher on lisinopril for nephroprotection should consult their nephrologist. The renal hemodynamics in advanced CKD are sensitive to blood pressure changes, and lisinopril's dose-titration in this population is already carefully managed. Adding another BP-active agent changes the calculation.

Patients who had lisinopril started after a myocardial infarction for left ventricular dysfunction are in a phase where blood pressure targets, remodeling, and loading conditions are being actively optimized. CoQ10 may ultimately be beneficial in this group, as Q-SYMBIO data suggest, but the timing and dose should be coordinated with the cardiologist.

Pregnant patients should not take CoQ10. Lisinopril is already contraindicated in pregnancy (FDA Category D/X). CoQ10 lacks adequate human pregnancy safety data.

Practical Takeaways for Patients and Clinicians

Asking your doctor "can I take CoQ10 with lisinopril?" is exactly the right question, and most clinicians will support a trial with monitoring. The evidence base does not show a dangerous interaction. It shows a manageable pharmacodynamic overlap that becomes clinically relevant only in patients whose blood pressure is already at target or who are prone to hypotension.

The quality of CoQ10 supplements varies widely. The US Pharmacopeia (USP) or NSF International certification on a label indicates that the product has been independently tested for label accuracy and contaminants. Choose a certified product over a generic supplement.

For patients on a statin plus lisinopril, the case for CoQ10 is arguably stronger than for a patient on lisinopril alone, given statin-related CoQ10 depletion documented in the Qu 2015 review. [7] A baseline CoQ10 plasma level (reference range: 0.5 to 1.5 mcg/mL) can help quantify any deficiency, though this test is not universally covered by insurance.

Bring a list of all supplements to every appointment. A 2021 JAMA Internal Medicine analysis found that 49% of patients do not disclose supplement use to their physicians. [14] That gap closes only when patients speak up.

Start CoQ10 at 100 mg/day with food, log your blood pressure twice daily for the first month, and share that log with your prescriber at your next visit.